 Israel's competition authority said Bristol-Myers Squibb has agreed to pay $2.7 million to settle a potential case over its blocking of a generic version for anti-cancer drug Imnavid. The antitrust agency said that Bristol and Neopharm Scientific, the Israeli distributor of Imnavid, declined a request by KS Kim International for drug samples to make a copycat for five months, which the competition authority said is too long for such an important drug.